Back to funds
View filing
Patient Square Capital LP
hedge fundUpdated 29 days agoManaged by Patient Square Capital Lp • Latest filing Q2 2026
Portfolio value
$645.5M
Q2 2026
Filings
14
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
61.8%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 14 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q1 2023 | $124.4M |
| Q2 2023 | $205.4M |
| Q3 2023 | $182M |
| Q4 2023 | $182.9M |
| Q1 2024 | $234.8M |
| Q2 2024 | $215.4M |
| Q3 2024 | $269.4M |
| Q4 2024 | $267.4M |
| Q1 2025 | $241.7M |
| Q2 2025 | $277.4M |
| Q3 2025 | $373.9M |
| Q4 2025 | $467.1M |
| Q1 2026 | $563.6M |
| Q2 2026 | $645.5M |
Top holdings
23 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | R ROIV ROIVANT SCIENCES LTD | $283.9M | 8.02M | 43.97% | — |
| 2 | R RVMDW REVOLUTION MEDICINES INC | $51.7M | 276.0K | 8.01% | — |
| 3 | M MIRM MIRUM PHARMACEUTICALS INC | $30.5M | 260.5K | 4.72% | — |
| 4 | A AAVXF ABIVAX SA | $27.5M | 206.5K | 4.26% | — |
| 5 | B BEIGF BEONE MEDICINES LTD | $25.7M | 90.0K | 3.97% | — |
| 6 | P PHVS PHARVARIS N V | $23.2M | 671.2K | 3.60% | — |
| 7 | A ARGX ARGENX SE | $21.3M | 23.0K | 3.31% | — |
| 8 | U UTHR UNITED THERAPEUTICS CORP DEL | $20.1M | 37.1K | 3.12% | — |
| 9 | B BLTE BELITE BIO INC | $16.9M | 110.0K | 2.62% | — |
| 10 | C COGT COGENT BIOSCIENCES INC | $16.4M | 425.0K | 2.55% | — |
| 11 | D DBVTF DBV TECHNOLOGIES S A | $14.9M | 909.5K | 2.31% | — |
| 12 | X XENE XENON PHARMACEUTICALS INC | $13.3M | 220.0K | 2.06% | — |
| 13 | B BNTX BIONTECH SE | $12.5M | 134.4K | 1.94% | — |
| 14 | R RCUS ARCUS BIOSCIENCES INC | $11M | 355.8K | 1.70% | — |
| 15 | E ELVN ENLIVEN THERAPEUTICS INC | $10.8M | 212.5K | 1.67% | — |
| 16 | D DNTH DIANTHUS THERAPEUTICS INC | $10.5M | 108.0K | 1.63% | — |
| 17 | A ALLO ALLOGENE THERAPEUTICS INC | $10.5M | 5.05M | 1.63% | — |
| 18 | ? N/A EYEPOINT INC | $10.3M | 720.0K | 1.59% | — |
| 19 | A ARQT ARCUTIS BIOTHERAPEUTICS INC | $9.7M | 370.0K | 1.50% | — |
| 20 | B BEPC C4 THERAPEUTICS INC | $7.5M | 1.61M | 1.16% | — |